ArticleiScience2026
A targeted DNA methylation method for detecting gastrointestinal cancer in circulating cell-free DNA.
Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Protocol for detecting cancer in blood using targeted DNA methylation.STAR protocols · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colorectal cancer (CRC) and gastric cancer (GC) are leading causes of cancer-related mortality. However, cost-effective methods for simultaneous detection of CRC and GC in circulating cell-free DNA (cfDNA) remain insufficiently explored. To address this, we developed targeted methylated CpG tandem amplification and sequencing (tMCTA-seq), a PCR-based method utilizing a set of locus-specific primers with a universal CGCGCGG primer, and targeted a panel of 110 loci. The method demonstrated high technical sensitivity below one haploid genome equivalent. Using a repeated nested cross-validation framework, the ensemble model, applied to 448 plasma samples (170 CRC, 101 GC, and 177 control participants), achieved areas under the curve (AUCs) of 0.928 (88.2% sensitivity and 90.7% specificity) for CRC and 0.926 (86.7% sensitivity and 94.4% specificity) for GC on the test set. Furthermore, tMCTA-seq differentiated between CRC and GC (AUC = 0.819). Thus, tMCTA-seq is a cost-effective, methylation-based approach for simultaneous detection of and differentiation between two major gastrointestinal cancers in blood.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.